BTIG starts ‘rapidly growing’ Tempus AI with a Buy

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing precision medicine platform technology company, which has “done a good job in its early days” to monetize its genomics and data business to medical oncologists and with pharma companies. While Tempus is now focused in cancer, the company looks to achieve similar scale across diseases, including in cardiology and beyond, and possesses one of the largest molecular libraries of cancer patients in the world, adds the analyst, who believes the company’s AI applications and data business represent “a significant free call option for investors.”